SCIENCE OF
POSSIBILITY
At Vertex, we invest in scientific innovation to create transformative medicines for people with serious diseases.
We announced updated data for our investigational cell therapy for the treatment of type 1 diabetes at the American Diabetes Association Scientific Sessions
We have published our 2024 Corporate Responsibility Report
Vertex researcher receives the 2025 Canada Gairdner International Award for pioneering research and discovery of medicines for cystic fibrosis
We've reported our fourth quarter and full year 2024 financial results
Our treatment for moderate-to-severe acute pain in adults is approved by the U.S. FDA
Working at Vertex
Our company is built on an inclusive culture that brings together the best and brightest in every field striving for one goal: to improve the lives of people with serious diseases.
Find a Vertex clinical trial
Volunteers who participate in clinical trials
help make new medicines a reality.
Featured stories
Guided by our uncompromising commitment to patients, we are committed to going the distance in cystic fibrosis. Learn more about what we're focused on as we continue our journey.
Our Community Champions program brings together a global network of Vertexians who are passionate about giving back to the communities where we live and work.
We are relentless in our quest to improve the lives of people living with serious diseases. Thanks to the dedication of teams led by Paul Negulescu, our medicines have profoundly impacted the cystic fibrosis community, earning recognition such as the prestigious Canada Gairdner International Award.
Guided by our uncompromising commitment to patients, we are committed to going the distance in cystic fibrosis. Learn more about what we're focused on as we continue our journey.
Our Community Champions program brings together a global network of Vertexians who are passionate about giving back to the communities where we live and work.
We are relentless in our quest to improve the lives of people living with serious diseases. Thanks to the dedication of teams led by Paul Negulescu, our medicines have profoundly impacted the cystic fibrosis community, earning recognition such as the prestigious Canada Gairdner International Award.
